Le Lézard
Classified in: Science and technology
Subjects: IPO, Statement

Arm Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering


Arm today announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of American depositary shares representing its ordinary shares. The size and price range for the proposed offering have yet to be determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act and other applicable securities laws.


These press releases may also interest you

at 02:08
Homestyler, a leading all-in-one 3D Design platform and creative community for global designers invested by Easyhome New Retail Group and Alibaba Group, successfully hosted the Homestyler Global Partners Conference and Gorgeous Home Imported Brand...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
ICEYE, a global leader in satellite-powered disaster management solutions, has announced a new data collaboration with Juniper Re, LLC ("Juniper Re"), the dynamic reinsurance broking arm and indirect subsidiary of BRP Group, Inc. . Juniper Re will...

at 02:00
CACI is delighted to announce that its Cygnum software will be used by the Environment Agency as a logistics planning tool to schedule its workforce and assets in the preparation of and response to incidents across England ranging from small...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: